Analyst
Oppenheimer
Equibles does not estimate personal net worth.
Leland Gershall is recorded as Analyst at Oppenheimer. Leland Gershall has spoken on 5 earnings calls and 1 other investor event across 4 companies, most recently for Ligand Pharmaceuticals Inc on October 29, 2026. Those appearances were for UroGen Pharma Ltd. (URGN), Ligand Pharmaceuticals Inc (LGND), Veru Inc. (VERU) and Tectonic Therapeutic, Inc. (TECX). The companies whose calls Leland Gershall spoke on are classified in the Healthcare sector.
“Just wondering, in terms of the cost synergies post ZOMA, just wondering, I think maybe it was on your last earnings call you had mentioned that those may be even better than you had originally expected.”
“Um, assuming success in, uh, in the plateau study, would you expect to, uh, need two, uh, phase threes or could you perhaps get by with one pivotal and perhaps use plateau, um, as supporters and also wanted to ask in, in further studies, uh, with another song, uh, given the development of, um, evolving agents for…”
“Just, Liz and team, wanted to ask, appreciate the additional launch metrics that you provided. Looks like you're making solid progress there on activated sites and prescribers.”
“We have two, one just on the commercial side with the story as you develop that market. I wanted to ask what you're seeing in terms of the community versus academic centers that are kind of buying into it.”
Oppenheimer
Analyst
Transcript header (unverified)
URGN
Biotechnology · Healthcare
VERU
Biotechnology · Healthcare
